Federal Register / Vol. 63, No. 105 /Tuesday, June 2, 1998 / Notices 30007

against C. trachomatis caused sexually

transmitted diseases. The variable

domains also represent the primary

serotyping antigenic determinants of C.

trachomatis organisms making these

variable domain sequences potential

useful targets for the development of

DNA or antibody based diagnostic

assays for C. trachomatis. The invention

is described further in Ying et al.,

Infection & Immunity 57, 1040–1049,

1989. Zhang et al., J. Infect. Dis. 176,

1035–1040, 1997 describes DNA

vaccines utilizing MOMP DNA.

Dated: May 21, 1998.

Jack Spiegel,

Director, Division of Technology,

Development and Transfer, Office of

Technology Transfer.

[FR Doc. 98–14496 Filed 6–1–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Pubic Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Applicator System And Method Of Use

MJ Lenardo, G Fisher (NIAID)

Serial No. 09/005,475 Filed 12 Jan 98

Licensing Contact: John FahnerVihtelic, 301/496–7735 ext. 270.

The present application describes a

novel microcentrifuge tube and tube cap

and research method, which allows for

dispensing the contents of a

microcentrifuge tube without pipetting.

The design eliminates pipetting volume

error and prevents the crosscontamination which can be

experienced in conventional pipetting.

This invention is particularly useful for

such applications as loading tube

contents into an electrophoresis gel after

a reaction such as PCR. Using the

disclosed apparatus and methods

increases the speed of a variety of

routine procedures and prevents

contamination of samples due to soiled

lab apparatus.

Linking Compounds Useful For

Coupling Carbohydrates To AmineContaining Carriers

P Kova, J Zhang (NIDDK)

Serial No. 60/069,686 Field 12 Dec 97

Licensing Contact: Robert Benson,

301/496–7056 ext. 267.

This invention describes an

inexpensive and easy method of linking

carbohydrates and carriers containing

an amino group to form

neoglycoconjugates. The resulting

neoglycoconjugates are useful as

vaccines (i.e., bacterial LPS or LOScarrier protein conjugate vaccines) or as

biologically active chromatographic

substrates (i.e., carbohydrates bound to

aminopropyl glass). The method

involves specific linkers that are easily

made from inexpensive commercially

available starting materials. The

carbohydrates to be used in the method

are limited only by the ability to convert

such carbohydrates into glycosyl

donors. Claimed are the linkers,

conjugates made with the linkers and

intermediates, and methods of

synthesizing the linkers and conjugates.

The invention is described in

Tetrahedron letters 39, 1091–1094,

1998.

System And Method For Intelligent

Quality Control Of A Process

JM DeLeo (CIT), AT Remaley (CC)

Serial No. 60/066,624 Filed 26 Nov 97

Licensing Contact: John FahnerVihtelic, 301/496–7735 ext. 270.

The present application is a

methodology for monitoring the quality

control of a process on-line for the

purpose of predicting and preventing

unusual/untoward events or failures in

that process. Such processes include

(but are not limited to) acquisition of

medical data from laboratory

instruments, assembly line

manufacturing, and general plant or

factory operations. The methodology is

based on a two-tiered automated

intelligent agent architecture. Intelligent

agents in the first tier are neural

networks trained to detect specific

errors for specific process environment

parameters. The single-agent second tier

is an expert system that integrates

inputs from first tier agents to derive

corrective action decisions that are

manually or automatically executed in

the process environment. Error

prevalence and wrong-decision cost

information are factored into the action

decision-making process. For clinical

laboratory instruments, the method

monitors patient laboratory data and

provides significant improvement in

quality control at reduced cost

compared to existing methods.

Identification Of The Human Pendred

Syndrome Gene

E Green, et al. (NHGRI)

DHHS Reference No. E–004–98/0 Filed

28 Oct 97

Licensing Contact: Dennis Penn, 301/

496–7065, ext. 211.

Pendred syndrome is a recessively

inherited disorder which was poorly

understood until the discovery of the

Pendred syndrome gene. This

syndrome, which is associated with

congenital deafness and thyroid goiter,

may account for upwards of 10% of

hereditary deafness. The gene encodes

for the protein pendrin which transports

sulfate across cell membranes. However,

the gene, when mutated, is responsible

for producing defective pendrin and

causing Pendred syndrome. Pendrin

therefore plays a key role in thyroid

function and the development and

functioning of the auditory system.

Learning how pendrin functions could

lead to a better understanding of thyroid

function and the development of the

auditory system. Finally, the resulting

knowledge into the genetic basis of

Pendred syndrome will allow for

improved diagnosis of syndromespecific mutations in at-risk individuals.

This research has been published in

Nature Genetics 1997 December;

17(4):411–22.

Local Magnetization Spoiling Using A

Gradient Insert For Reducing The Field

Of View In Magnetic Resonance

Imaging

DG Wiesler, H Wen, RS Balaban, SD

Wolff (NHLBI)

Serial No. 60/043,292 Filed 11 Apr 97

Licensing Contact: John FahnerVihtelic, 301/496–7735, ext. 270.

The present invention provides a

method and device for eliminating alias

artifacts encountered in MRI when the

field of view is made smaller than the

subject being imaged. Significant
30008 Federal Register / Vol. 63, No. 105 /Tuesday, June 2, 1998 / Notices

advantages accrue from reducing the

field of view to a smaller region of

interest. These include reduced imaging

time, increased spatial and temporal

resolution, and less susceptibility to

motion artifacts. The device operates by

dephasing the magnetic resonance

signal in regions away from the region

of interest by means of a gradient insert.

Nitrogen-Containing Cylohetero

Cycloalkyl-Aminoaryl Derivatives For

CNS Disorders

BR DeCosta, et al. (NIDDK)

Serial No. 07/473,008 Filed 31 Jan 90

(U.S. Patent 5,130,330 Issued on 14 Jul

92); Serial No. 07/877,190 Filed 01 Jul

92 (U.S. Patent 5,739,158 Issued on 14

Apr 98); Serial No. 08/335,532 Filed 07

Nov 94

Licensing Contact: Charles Maynard,

301/496–7735, ext. 243.

This technology includes

compositions for a novel family of

nitrogen containing cyclohetero

cycloalkyl-aminoaryl compounds for

use in the field of clinical neurology.

The intellectual property relates

specifically to a class of therapeutically

useful compounds for the treatment of

central nervous system (CNS) disorders

such as cerebral ischemia, psychotic

disorders and convulsions. These

compounds are particularly useful for

treating neurotoxic injury which follow

periods of hypoxia, anoxia or ischemia

associated with stroke, cardiac arrest or

perinatal asphyxia.

The novel semirigid derivatives (+)-

cis-1-[2-phenyl-2-

bicyclo[3,1,0]hexyl]piperidine [(+)-8],

its enantiomer (¥)-8, and (+¥)-trans-1-

[2-phenyl-2-bicylo [3,1,0]piperidine [(+/

¥)-9] are illustrative examples of this

family of compounds which may be

used to treat CNS disorders and diseases

such as cerebral ischemia, psychotic

disorders and convulsions, as well as

prevention of neurotoxic damage and

neurodegenerative disease via a unique

receptor mechanism. This class of

compounds produce neuroprotective

effects by a different mechanism to

phencyclidine and metaphit a noncompetitive N-methyl-D-aspartic acid

antagonis.

Dated: May 21, 1998.

Jack Spiegel,

Director, Division of Technology,

Development, and Transfer, Office of

Technology Transfer.

[FR Doc. 98–14497 Filed 6–1–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: Prostate, Lung, Colorectal,

and Ovarian Cancer (PLCO) Cancer Screening

Trial Expansion.

Date: June 8–9, 1998.

Time: June 8—8:00 a.m. to recess; June 9—

8:00 a.m. to Adjournment.

Place: Double Tree Hotel-Rockville, 1750

Rockville Pike, Rockville, MD 20852.

Contact Person: Wilna Woods, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 622B, 6130 Executive Boulevard, MSC

7405, Bethesda, MD 20892–7405, Telephone:

301/496–7903.

Purpose/Agenda: To review, discuss and

evaluate responses to a Request for Proposal.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Proposals and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower,

93.399, Cancer Control.)

Dated: May 22, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–14494 Filed 6–1–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health;

Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following meeting

of the National Institute of Mental

Health Special Emphasis Panel:

Agenda/Purpose: To review and evaluate

grant applications.

Committee Name: National Institute of

Mental Health Special Emphasis Panel.

Date: June 24, 1998.

Time: 8:30 a.m.

Place: Chevy Chase Holiday Inn, 5520

Wisconsin Avenue, Chevy Chase, MD 20815.

Contact Person: W. Gregory Zimmerman,

Parklawn, Room 9C–18, 5600 Fishers Lane,

Rockville, Md 20857, Telephone: 301, 443–

1340.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers 93.242, 93.281, 93.282)

Dated: May 22, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98–14493 Filed 6–1–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; National and

Regional Meetings of the National

Reading Panel

Notice is hereby given of five regional

meetings and one national meeting of

the National Reading Panel. The

regional meetings will be held on May

29, 1998, in Chicago, Illinois; June 5,

1998, in Portland Oregon, June 8, 1998,

in Houston, Texas; June 23, 1998 in

New York City, New York; and July 9,

1998, in Jackson, Mississippi. The

national meeting will be held July 24,

1998, in Bethesda, Maryland. The

regional meeting in Chicago will take

place at Illinois Room at the Chicago

Circle Center (CCC), University of

Illinois at Chicago, 750 South Halsted

Street, Chicago, IL 60607. The Chicago

meeting will begin at 9:30 a.m. and is

expected to adjourn at 4:00 p.m. The

entire meeting will be open to the

public. The precise times and sites for

the other meetings listed will be

published when the plans for the

meetings at those sites are finalized.

The National Reading Panel was

requested by Congress and created by

the Director of the National Institute of

Child Health and Human Development

in consultation with the Secretary of

Education. The Panel will study the